<DOC>
	<DOCNO>NCT00469599</DOCNO>
	<brief_summary>The purpose study compare alfacalcidol paricalcitol treatment secondary hyperparathyroidism hemodialysis patient .</brief_summary>
	<brief_title>Treatment Secondary Hyperparathyroidism Uremic Patient</brief_title>
	<detailed_description>Secondary hyperparathyroidism common feature patient chronic kidney disease . Its clinical consequence include renal osteodystrophy , calciphylaxia potentially vascular calcification increase morbidity mortality . Reduced synthesis active vitamin D contribute secondary hyperparathyroidism . Therefore primarily manage condition activate vitamin D. In Denmark alfacalcidol primary choice vitamin D analog . However hypercalcemia hyperphosphatemia may limit use alfacalcidol therapy due increase risk vascular calcification mortality . Therefore new vitamin D analog , paricalcitol , develop , may less prone develop hypercalcemia hyperphosphatemia . However randomise control clinical study compare alfacalcidol paricalcitol never perform . The primary objective study evaluate effect alfacalcidol paricalcitol intact parathyroid hormone level tendency towards hyperphosphatemia hypercalcemia . The study perform 117 patient end stage renal failure maintenance hemodialysis therapy 6 different Danish hemodialysis unit . The design multicenter crossover study patient randomize two treatment arm . After wash period 6 week receive alfacalcidol paricalcitol period 16 week wash period 6 week receive contrary treatment ( respectively paricalcitol alfacalcidol ) 16 week . The initial dose alfacalcidol ( 1 μg intravenously dialysis ) paricalcitol ( 3 μg intravenously dialysis ) adjust every second week base iPTH , p-calcium p-phosphate . P-calcium , p-phosphate , iPTH , pulse blood pressure measure every second week . By begin end period treatment , alkaline phosphatase , 25OH-D3 , 1,25 ( OH ) 2 vitamin D safety parameter measure , pulse wave velocity pulse wave analysis perform subgroup . Alfacalcidol paricalcitol register treatment modality patient renal failure secondary hyperparathyroidism perform risk safety enrol patient well blood sample blood pressure measurement perform risk either .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<criteria>1 . &gt; 18 year old 2 . Secondary hyperparathyroidism ; iPTH &gt; 350 pg/ml treatment 6 week without treatment vitamin D. 3 . Chronic renal insufficiency receive hemodialysis . 4 . Pphosphate &lt; 1,8 mmol/l 5 . Pcalcium ion &lt; 1,25 mmol/l 6 . Receiving maximal possible dose calciumbased phosphate binder . 7 . Accepting 2 x 6 week without vitamin D. 8 . Safe anti conception fertile woman 9 . Do expect need calcimimetics parathyroidectomy next year . 10 . Written informed consent . 1 . Malignancy 2 . Disease condition make patient unable participate 3 . Expected lifetime less one year . 4 . Pregnancy nurse 5 . Allergic content Zemplar Etalpha 6 . Currently receive calcimimetics 7 . Participating clinical intervention study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Hyperparathyroidism , Secondary</keyword>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
	<keyword>Vitamin D Deficiency</keyword>
	<keyword>Renal Osteodystrophy</keyword>
	<keyword>Hemodialysis</keyword>
</DOC>